dichlorphenamide

Absorption: Well absorbed following oral administration.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-Life: Unknown.

Time/Action Profile ⬆ ⬇

ROUTE	ONSET	PEAK	DURATION
PO	unknown	unknown	unknown

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Hypersensitivity or cross-sensitivity with sulfonamides;
Severe pulmonary obstruction;
Concurrent use of high-dose aspirin.
Hepatic impairment;

Use Cautiously in:

Concurrent use of low-dose aspirin;
Adrenocortical excess or renal tubular acidosis (↑ risk of hypokalemia);
OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk;
Lactation: Safety not established in breastfeeding;
Pedi: Safety and effectiveness not established in children;
Geri: ↑risk of falls and metabolic acidosis in older adults.

Adv. Reactions/Side Effects ⬆ ⬇

Derm: pruritus, rash, STEVENS-JOHNSON SYNDROME

EENT: pharyngolaryngeal pain

F and E: hyperchloremic non-anion gap metabolic acidosis, hypokalemia

GI: diarrhea, nausea

Hemat: APLASTIC ANEMIA, HEMOLYTIC ANEMIA, LEUKOPENIA

Metab: weight loss

MS: arthralgia, muscle spasms/twitching

Neuro: confusion, drowsiness, dysgeusia, paresthesias, fatigue

Resp: dyspnea

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions ⬆ ⬇

Drug-drug:

May ↑ risk of toxicity of aspirin; concurrent use with high-dose aspirin may result in anorexia, lethargy, and coma and is contraindicated..
Antifungals, laxatives, loop diuretics, penicillin, thiazide diuretics andtheophylline may ↑ risk of hypokalemia.
Drugs that cause hyperchloremic metabolic acidosis may ↑ risk and severity of metabolic acidosis.
May ↑ levels and risk of toxicity of amphetamines,quinidine, procainamide, and possibly tricyclic antidepressants.

Route/Dosage ⬆ ⬇

PO (Adults ): 50 mg once or twice daily; titrate according to response (not to exceed 200 mg/day).

Availability ⬆ ⬇

(Generic available)

Tablets: 50 mg

Assessment ⬆ ⬇

Assess patient for signs/symptoms of hypokalemia (muscle weakness, malaise, fatigue, ECG changes, vomiting).
- Assess for allergy to sulfonamides. If rash or signs and symptoms of hypersensitivity reaction (Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, other blood dyscrasias) occur, discontinue dichlorphenamide. Pulmonary involvement can occur in isolation or as part of a systemic reaction.
- Monitor for signs/symptoms of hemolytic anemia (weakness, dizziness, pallor, jaundice, splenomegaly, abdominal pain), leukopenia, or aplastic anemia.
- Monitor for falls. Risk ↑ in older adults and at high doses. If falls occur, consider dose ↓ or discontinuation.

Lab Test Considerations:

Monitor potassium at baseline and periodically during therapy. If hypokalemia occurs, consider ↓ dose or discontinuing therapy.
- May cause hyperchloremic non-anion gap metabolic acidosis. Monitor bicarbonate at baseline and periodically during therapy. If metabolic acidosis occurs, consider ↓ dose or discontinuing therapy.

Implementation ⬆ ⬇

PO: Administer once or twice daily.

Patient/Family Teaching ⬆ ⬇

Explain purpose and side effects of dichlorphenamide. Instruct patient to take as directed. Advise patient to read Patient Information before starting and with each Rx refill in case of changes.
Caution patient to discontinue therapy and notify health care professional is rash or signs/symptoms of allergic reaction occur.
Instruct patient to report signs/symptoms of hypokalemia.
Advise patient to report worsening symptoms of periodic paralysis to health care professional.
May occasionally cause drowsiness. Caution patient to avoid driving and other activities that require alertness until response to the drug is known.
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications, especially aspirin.
Rep: Advise patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding. Monitor newborns of mothers treated with dichlorphenamide for metabolic acidosis.

Evaluation/Desired Outcomes ⬆ ⬇

Reduced incidence/severity of muscle weakness associated with periodic paralysis.

US Brand Names ⬆ ⬇

Code ⬆

NDC Code

13668- Torrent pharmaceuticals limited
- 13668-676- Dichlorphenamide
  - 13668-676-01- 100 TABLET in 1 BOTTLE (13668-676-01)

13668- Torrent pharmaceuticals limited
- 13668-676- Dichlorphenamide
  - 13668-676-30- 30 TABLET in 1 BOTTLE (13668-676-30)

58159- NURAY CHEMICALS PRIVATE LIMITED
- 58159-071-
  - 58159-071-01- 35 kg in 1 DRUM (58159-071-01)

58159- NURAY CHEMICALS PRIVATE LIMITED
- 58159-071-
  - 58159-071-02- 20 kg in 1 DRUM (58159-071-02)

58159- NURAY CHEMICALS PRIVATE LIMITED
- 58159-071-
  - 58159-071-03- 15 kg in 1 DRUM (58159-071-03)

58159- NURAY CHEMICALS PRIVATE LIMITED
- 58159-071-
  58159-071-04- 10 kg in 1 DRUM (58159-071-04)

58159- NURAY CHEMICALS PRIVATE LIMITED
- 58159-071-
  58159-071-05- 5 kg in 1 DRUM (58159-071-05)

59651- Aurobindo Pharma Limited
- 59651-223-
  59651-223-37- 50 kg in 1 DRUM (59651-223-37)

70709- Cycle Pharmaceuticals Ltd.
- 70709-085- ORMALVI
  70709-085-10- 100 TABLET in 1 BOTTLE (70709-085-10)

71090- Strongbridge US Inc.
- 71090-001- Keveyis
  - 71090-001-01- 100 TABLET in 1 BOTTLE (71090-001-01)

72065- Xeris Pharmaceuticals, Inc.
- 72065-001- Keveyis
  - 72065-001-01- 100 TABLET in 1 BOTTLE (72065-001-01)

73435- Biophore India Pharmaceuticals Pvt. Ltd
- 73435-011-
  - 73435-011-11- 15 kg in 1 DRUM (73435-011-11)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇